Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report

Si-Man Huang; Tao Tao; Chao-Ling Wan; Tian-Mei Wu; Han-Yu Cao; Yan Qiu; Xiang-Dong Shen; Bin-Ru Wang; Shuai-Shuai Ge; Yan-Yan Li; Tong-Tong Zhang; Bing Wu; Sheng-Li Xue

doi:10.1002/ccr3.6688

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report

Clin Case Rep. 2023 Jan 3;11(1):e6688. doi: 10.1002/ccr3.6688. eCollection 2023 Jan.

Authors

Si-Man Huang^{1

2}, Tao Tao^{3

4}, Chao-Ling Wan^{1

2}, Tian-Mei Wu^{1

2}, Han-Yu Cao^{1

2}, Yan Qiu^{1

2}, Xiang-Dong Shen^{1

2}, Bin-Ru Wang^{1

2}, Shuai-Shuai Ge^{1

2}, Yan-Yan Li^{1

2}, Tong-Tong Zhang^{1

2}, Bing Wu⁵, Sheng-Li Xue^{1

2}

Affiliations

¹ National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology Soochow University Suzhou China.
³ Department of Respiratory and Critical Medicine the Fifth People's Hospital of Suzhou Suzhou China.
⁴ Department of Respiratory and Critical Medicine the Affiliated Infectious Diseases Hospital of Soochow University Suzhou China.
⁵ Suzhou Hospital of Chinese Traditional Medicine the Affiliated Hospital of Nanjing University of Chinese Traditional Medicine Suzhou China.

Abstract

Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) is a rare type of AML with a low survival rate and poor prognosis. We first report a Ph + AML patient who remained in long-term remission after the combination of flumatinib and venetoclax, which could provide corresponding treatment ideas for clinical practice.

Keywords: Philadelphia chromosome‐positive acute myeloid leukemia; flumatinib; regimen; venetoclax.

Publication types

Case Reports